tbuckley/cabot-search huggingface dataset:
Postoperative Atrial Fibrillation After Noncardiac Surgery and Stroke
Authors: Shi-Min Hu, Xiang-Hua Fang, Hai-Feng Li
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pregnancy-induced humoral sensitization overrides T cell tolerance to fetus-matched allografts in mice
Authors: Ashley N. Suah, Dong-Kha V. Tran, Stella H.W. Khiew, Michael S. Andrade, Jared M. Pollard, Dharmendra Jain, James S. Young, Dengping Yin, Geetha Chalasani, Maria-Luisa Alegre, Anita S. Chong
Journal: Journal of Clinical Investigation (2021)

Immunological tolerance to semiallogeneic fetuses is necessary to achieving successful first pregnancy and permitting subsequent pregnancies with the same father. Paradoxically, pregnancy is an important cause of sensitization, resulting in the accelerated rejection of offspring-matched allografts. The underlying basis for divergent outcomes following reencounter of the same alloantigens on transplanted organs versus fetuses in postpartum females is incompletely understood. Using a mouse model that allows concurrent tracking of endogenous fetus-specific T and B cell responses in a single recipient, we show that semiallogeneic pregnancies simultaneously induce fetus-specific T cell tolerance and humoral sensitization. Pregnancy-induced antibodies, but not B cells, impeded transplantation tolerance elicited by costimulation blockade to offspring-matched cardiac grafts. Remarkably, in B cell–deficient mice, allogeneic pregnancy enabled the spontaneous acceptance of fetus-matched allografts. The presence of pregnancy-sensitized B cells that cannot secrete antibodies at the time of heart transplantation was sufficient to precipitate rejection and override pregnancy-established T cell tolerance. Thus, while induction of memory B cells and alloantibodies by pregnancies establishes formidable barriers to transplant success for multigravid women, our observations raise the possibility that humoral desensitization will not only improve transplantation outcomes, but also reveal an unexpected propensity of multiparous recipients to achieve tolerance to offspring-matched allografts.
Balancing the Risks and Benefits of Benzodiazepines
Authors: Matthew E. Hirschtritt, Mark Olfson, Kurt Kroenke
Journal: JAMA (2021)

Following a September 2020 FDA announcement of a boxed warning for benzodiazepines, this Viewpoint reviews the relative benefits and risks of the drugs to reduce overuse in at-risk patients, moderate underuse in clinically appropriate instances, and guide judicious, rational prescribing.
Abstract #4340: High-throughput somatic mutation profiling in cancer using the Illumina GoldenGate® Assay
Authors: Erich Jaeger, Gabriel Capella, Jose Costa, Jian-Bing Fan
Journal: Cancer Research (2009)

Purpose: To further develop the application of the GoldenGate Assay for high-throughput screening of up to 1536 somatic mutations in clinical cancer specimens. Experimental Procedures: Assays for 192 somatic mutations were selected from an initial set of over 300 assays targeting mutant alleles in 40 genes frequently mutated in a variety of tumor types. Pancreatic cancer samples collected from tumor tissue, serum, and stool were used to test these assays. Normal human Coriell DNA samples were also screened to obtain baseline intensity data for background normalization of the clinical samples. All samples were quantified by PicoGreen, whole-genome amplified, and screened with the assay pool. To test assay sensitivity, oligos each containing one of 31 different mutations in TP53 and Kras were also spiked into a normal sample and screened in parallel. Finally, samples with high relative mutant signal intensities were mixed with normal samples in varying amounts to further test assay sensitivity for additional targets. Results: Separating assays for mutant alleles into multiple pools resulted in improved assay performance in detecting both the normal alleles and spiked-in mutant alleles. Whole-genome amplification was effective, but clinical samples with A260/230   Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4340.
D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy
Authors: Chuanchao Du, Mengxue Zhou, Fei Jia, Lifo Ruan, Huiru Lu, Jiayu Zhang, Bin Zhu, Xiaoguang Liu, Jun Chen, Zhifang Chai, Yi Hu
Journal: Biomaterials (2021)
Atorvastatin is associated with reduced cisplatin-induced hearing loss
Authors: Katharine A. Fernandez, Paul Allen, Maura Campbell, Brandi Page, Thomas Townes, Chuan-Ming Li, Hui Cheng, Jaylon Garrett, Marcia Mulquin, Anna Clements, Deborah Mulford, Candice Ortiz, Carmen Brewer, Judy R. Dubno, Shawn Newlands, Nicole C. Schmitt, Lisa L. Cunningham
Journal: Journal of Clinical Investigation (2021)

BACKGROUNDCisplatin is widely used to treat adult and pediatric cancers. It is the most ototoxic drug in clinical use, resulting in permanent hearing loss in approximately 50% of treated patients. There is a major need for therapies that prevent cisplatin-induced hearing loss. Studies in mice suggest that concurrent use of statins reduces cisplatin-induced hearing loss.METHODSWe examined hearing thresholds from 277 adults treated with cisplatin for head and neck cancer. Pretreatment and posttreatment audiograms were collected within 90 days of initiation and completion of cisplatin therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).RESULTSAmong patients on concurrent atorvastatin, 9.7% experienced a CTCAE grade 2 or higher cisplatin-induced hearing loss compared with 29.4% in nonstatin users (P < 0.0001). A mixed-effect model analysis showed that atorvastatin use was significantly associated with reduced cisplatin-induced hearing loss (P ≤ 0.01). An adjusted odds ratio (OR) analysis indicated that an atorvastatin user is 53% less likely to acquire a cisplatin-induced hearing loss than a nonstatin user (OR = 0.47; 95% CI, 0.30-0.78). Three-year survival rates were not different between atorvastatin users and nonstatin users (P > 0.05).CONCLUSIONSOur data indicate that atorvastatin use is associated with reduced incidence and severity of cisplatin-induced hearing loss in adults being treated for head and neck cancer.TRIAL REGISTRATIONClinicalTrials.gov identifier NCT03225157.FUNDINGFunding was provided by the Division of Intramural Research at the National Institute on Deafness and Other Communication Disorders (1 ZIA DC000079, ZIA DC000090).
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes
Authors: David A. Sallman, Amy E. DeZern, Guillermo Garcia-Manero, David P. Steensma, Gail J. Roboz, Mikkael A. Sekeres, Thomas Cluzeau, Kendra L. Sweet, Amy McLemore, Kathy L. McGraw, John Puskas, Ling Zhang, Jiqiang Yao, Qianxing Mo, Lisa Nardelli, Najla H. Al Ali, Eric Padron, Greg Korbel, Eyal C. Attar, Hagop M. Kantarjian, Jeffrey E. Lancet, Pierre Fenaux, Alan F. List, Rami S. Komrokji
Journal: Journal of Clinical Oncology (2021)

Approximately 20% of patients with
Association of Oily and Nonoily Fish Consumption and Fish Oil Supplements With Incident Type 2 Diabetes: A Large Population-Based Prospective Study
Authors: Guo-Chong Chen, Rhonda Arthur, Li-Qiang Qin, Li-Hua Chen, Zhendong Mei, Yan Zheng, Yang Li, Tao Wang, Thomas E. Rohan, Qibin Qi
Journal: Diabetes Care (2021)

OBJECTIVE To evaluate associations of oily and nonoily fish consumption and fish oil supplements with incident type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We included 392,287 middle-aged and older participants (55.0% women) in the UK Biobank who were free of diabetes, major cardiovascular disease, and cancer and had information on habitual intake of major food groups and use of fish oil supplements at baseline (2006–2010). Of these, 163,706 participated in one to five rounds of 24-h dietary recalls during 2009–2012. RESULTS During a median 10.1 years of follow-up, 7,262 incident cases of T2D were identified. Compared with participants who reported never consumption of oily fish, the multivariable-adjusted hazard ratios of T2D were 0.84 (95% CI 0.78–0.91), 0.78 (0.72–0.85), and 0.78 (0.71–0.86) for those who reported &amp;lt;1 serving/week, weekly, and ≥2 servings/week of oily fish consumption, respectively (P-trend &amp;lt; 0.001). Consumption of nonoily fish was not associated with risk of T2D (P-trend = 0.45). Participants who reported regular fish oil use at baseline had a 9% (95% CI 4–14%) lower risk of T2D compared with nonusers. Baseline regular users of fish oil who also reported fish oil use during at least one of the 24-h dietary recalls had an 18% (8–27%) lower risk of T2D compared with constant nonusers. CONCLUSIONS Our findings suggest that consumption of oily fish but not nonoily fish was associated with a lower risk of T2D. Use of fish oil supplements, especially constant use over time, was also associated with a lower risk of T2D.
IL-5による刺激後におけるテオフィリン、糖質コルチコイドとマクロライド剤に起因する好酸球アポトーシス
Authors: Adachi T, Motojima S, Hirata A, Fukuda T, Kihara N, Kosaku A, Ohtake H, Makino S
Journal: Journal of Allergy and Clinical Immunology (1996)
RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse
Authors: Jaebeom Cho, Hye-Young Min, Ho Jin Lee, Seung Yeob Hyun, Jeong Yeon Sim, Myungkyung Noh, Su Jung Hwang, Shin-Hyung Park, Hye-Jin Boo, Hyo-Jong Lee, Sungyoul Hong, Rang-Woon Park, Young Kee Shin, Mien-Chie Hung, Ho-Young Lee
Journal: Journal of Clinical Investigation (2021)

Slow-cycling/dormant cancer cells (SCCs) have pivotal roles in driving cancer relapse and drug resistance. A mechanistic explanation for cancer cell dormancy and therapeutic strategies targeting SCCs are necessary to improve patient prognosis, but are limited because of technical challenges to obtaining SCCs. Here, by applying proliferation-sensitive dyes and chemotherapeutics to non–small cell lung cancer (NSCLC) cell lines and patient-derived xenografts, we identified a distinct SCC subpopulation that resembled SCCs in patient tumors. These SCCs displayed major dormancy-like phenotypes and high survival capacity under hostile microenvironments through transcriptional upregulation of regulator of G protein signaling 2 (RGS2). Database analysis revealed RGS2 as a biomarker of retarded proliferation and poor prognosis in NSCLC. We showed that RGS2 caused prolonged translational arrest in SCCs through persistent eukaryotic initiation factor 2 (eIF2α) phosphorylation via proteasome-mediated degradation of activating transcription factor 4 (ATF4). Translational activation through RGS2 antagonism or the use of phosphodiesterase 5 inhibitors, including sildenafil (Viagra), promoted ER stress–induced apoptosis in SCCs in vitro and in vivo under stressed conditions, such as those induced by chemotherapy. Our results suggest that a low-dose chemotherapy and translation-instigating pharmacological intervention in combination is an effective strategy to prevent tumor progression in NSCLC patients after rigorous chemotherapy.
Photodynamic/ photothermal therapy enhances neutrophil-mediated ibrutinib tumor delivery for potent tumor immunotherapy: More than one plus one?
Authors: Qiujun Qiu, Cong Li, Xinyang Yan, Hongxia Zhang, Xiang Luo, Xin Gao, Xinrong Liu, Yanzhi Song, Yihui Deng
Journal: Biomaterials (2021)
MO01.48 INSIGHT 2: Tepotinib + Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
Authors: E. Smit, E. Felip, N. Karachaliou, B. Ellers-Lenz, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2021)
COVID‐19‐related dermatosis in November 2019: could this case be Italy’s patient zero?
Authors: R. Gianotti, M. Barberis, G. Fellegara, C. Galván‐Casas, E. Gianotti
Journal: British Journal of Dermatology (2021)

Milan, the largest city in northern Italy, was one of the first European metropolitan areas to be affected by the COVID-19 pandemic. We analyzed skin biopsies of patients from Milan with dermatoses and positive PCR swabs for SARS-CoV-2 at different stages of the infection (1,2). The results were compared to skin biopsies of 20 COVID-19 non-diagnosed patients with dermatoses, who were at high-risk of COVID-19 infection.
Endemic SARS-CoV-2 will maintain post-pandemic immunity
Authors: Marc Veldhoen, J. Pedro Simas
Journal: Nature reviews. Immunology (2021)

COVID-19 vaccinations have started. They will stop the pandemic. Citing recent data that are in line with immunological knowledge and predictions, combined with insights of common cold coronaviruses, we here set out the case that the maintenance of population immunity will not depend on continued vaccinations but on the endemic presence of SARS-CoV-2. Here, Veldhoen and Simas discuss why immunity to SARS-CoV-2 in populations may ultimately be driven by the endemic presence of the virus and not rely on continued mass vaccination programmes.
John Spalding: neurologist who helped to develop mechanical ventilation
Authors: John Illman
Journal: BMJ (2021)

John Spalding was one of the pioneers of artificial respiration. An old Etonian, he was one of the Oxford team in the early 1950s that developed the East Radcliffe ventilator—it included a Sturmey Archer bicycle gear to change the respiratory rate and a humidifier modelled from a domestic pressure cooker.

It evolved after the team had been in Copenhagen in 1952, at the epicentre of one of the world’s most devastating polio epidemics. The city had only one iron lung for 1.2 million people. About 1000 medical and dental students working in relays for weeks kept hundreds of paralysed polio patients alive by squeezing air filled bags by hand with tracheostomies—this was the catalyst for Europe’s first intensive care unit.

Lacking student volunteers, the Oxford team vowed to make a machine. Interviewed by Oxford Medicine , the Oxford medical alumni newsletter, in 2005, Spalding recalled: “It was a splendid respirator because it was absolutely basic. A nurse could look at it for a couple of minutes and understand it exactly. If anything went wrong, she would know and know what to do about it.

“It had a simple device to change from mains to …
Abstract 13488: Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58
Authors: Remo H Furtado, Marc P Bonaca, Thomas A Zelniker, Itamar Raz, Erica Goodrich, Ofri Mosenzon, Sabina Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John Wilding, Ingrid A Gause-Nilsson, Anna Maria Langkilde, Marc S Sabatine, Stephen Wiviott
Journal: Circulation (2019)

Introduction: Sodium glucose transporter 2 inhibitors (SGLT2i) reduce the risk of major adverse cardiovascular events (MACE), including myocardial infarction (MI), in patients with type 2 diabetes ...
A novel PGAM5 inhibitor LFHP-1c protects blood–brain barrier integrity in ischemic stroke
Authors: Chenglong Gao, Yazhou Xu, Zhuangzhuang Liang, Yunjie Wang, Qinghong Shang, Shengbin Zhang, Cunfang Wang, Mingmin Ni, Dalei Wu, Zhangjian Huang, Tao Pang
Journal: Acta Pharmaceutica Sinica B (2021)

Blood–brain barrier (BBB) damage after ischemia significantly influences stroke outcome. Compound LFHP-1c was previously discovered with neuroprotective role in stroke model, but its mechanism of action on protection of BBB disruption after stroke remains unknown. Here, we show that LFHP-1c, as a direct PGAM5 inhibitor, prevented BBB disruption after transient middle cerebral artery occlusion (tMCAO) in rats. Mechanistically, LFHP-1c binding with endothelial PGAM5 not only inhibited the PGAM5 phosphatase activity, but also reduced the interaction of PGAM5 with NRF2, which facilitated nuclear translocation of NRF2 to prevent BBB disruption from ischemia. Furthermore, LFHP-1c administration by targeting PGAM5 shows a trend toward reduced infarct volume, brain edema and neurological deficits in nonhuman primate Macaca fascicularis model with tMCAO. Thus, our study identifies compound LFHP-1c as a firstly direct PGAM5 inhibitor showing amelioration of ischemia-induced BBB disruption in vitro and in vivo, and provides a potentially therapeutics for brain ischemic stroke.
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
Authors: Marcos V. P. Gondim, Scott Sherrill-Mix, Frederic Bibollet-Ruche, Ronnie M. Russell, Stephanie Trimboli, Andrew G. Smith, Yingying Li, Weimin Liu, Alexa N. Avitto, Julia C. DeVoto, Jesse Connell, Angharad E. Fenton-May, Pierre Pellegrino, Ian Williams, Emmanouil Papasavvas, Julio C. C. Lorenzi, D. Brenda Salantes, Felicity Mampe, M. Alexandra Monroy, Yehuda Z. Cohen, Sonya Heath, Michael S. Saag, Luis J. Montaner, Ronald G. Collman, Janet M. Siliciano, Robert F. Siliciano, Lindsey J. Plenderleith, Paul M. Sharp, Marina Caskey, Michel C. Nussenzweig, George M. Shaw, Persephone Borrow, Katharine J. Bar, Beatrice H. Hahn
Journal: Science Translational Medicine (2021)

Interferon-mediated pressures vary throughout HIV-1 infection but are the highest during viral rebound after treatment interruption.
Tofacitinib as Treatment for Nail Lichen Planus Associated With Alopecia Universalis
Authors: Matilde Iorizzo, Eckart Haneke
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
RO01.01 Prospective Evaluation of Ipilimumab and Nivolumab in Patients with Non-Small Cell Lung Cancer Brain Metastasis
Authors: A. Juloori, C. Bestvina, S. Pitroda, K. Pointer, M. Jelinek, P. Hoffman, E. Vokes, J. Patel, S. Chmura
Journal: Journal of Thoracic Oncology (2021)
Abstract 14679: Differences in Long-term Outcomes Among Survivors of In-Hospital Cardiac Arrest
Authors: Lena M Chen, Brahmajee K Nallamothu, John A Spertus, Paul S Chan
Journal: Circulation (2017)

Introduction: Racial differences for in-hospital survival exist among patients with an in-hospital cardiac arrest (IHCA). However, whether there are racial differences in long-term survival among s...
Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites
Authors: Silvia Uccella, Stefano La Rosa, Jasna Metovic, Deborah Marchiori, Jean-Yves Scoazec, Marco Volante, Ozgur Mete, Mauro Papotti
Journal: Endocrine Pathology (2021)
Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis
Authors: Irina Gessl, Mihaela Popescu, Victoria Schimpl, Gabriela Supp, Thomas Deimel, Martina Durechova, Miriam Hucke, Michaela Loiskandl, Paul Studenic, Michael Zauner, Josef S Smolen, Daniel Aletaha, Peter Mandl
Journal: Annals of the Rheumatic Diseases (2021)

To determine whether clinical tenderness can be considered a sign of inflammatory joint activity in patients with rheumatoid arthritis (RA), osteoarthritis (OA) or psoriatic arthritis (PsA) and to assess other possible factors associated with tenderness.Patients diagnosed with RA, PsA and OA underwent clinical and ultrasound examination of wrists and finger joints. Radiographs of the hands were scored for erosions, joint space narrowing (JSN), osteophytes and malalignment. A binary damage score (positive if ≥1 erosion, JSN and/or presence of malalignment) was calculated. Differences in grey scale signs of synovitis and power Doppler (PD) between tender non-swollen (TNS) versus non-tender non-swollen (NTNS) joints were calculated. Disease duration was assessed,<2 years was regarded as early and >5 years as long-standing arthritis.In total, 34 patients (9 early and 14 long-standing) from patients with RA, 31 patients (7 early and 15 long-standing) with PsA and 30 with OA were included. We found equal frequencies of PD signal between TNS and NTNS joints in RA (p=0.18), PsA (p=0.59) or OA (p=0.96). However, PD had a significant association with tenderness in early arthritis both in RA (p=0.02) and in PsA (p=0.02). The radiographic damage score showed significant association with tenderness in RA (p<0.01), PsA (p<0.01) and OA (p=0.04).Tenderness might not always be a sign of active inflammation in RA, PsA and OA. While tenderness in early arthritis may be more related to inflammation, established disease is better explained by joint damage and malalignment.
Intracellular immune sensing promotes inflammation via gasdermin D–driven release of a lectin alarmin
Authors: Ashley J. Russo, Swathy O. Vasudevan, Santiago P. Méndez-Huergo, Puja Kumari, Antoine Menoret, Shivalee Duduskar, Chengliang Wang, Juan M. Pérez Sáez, Margaret M. Fettis, Chuan Li, Renjie Liu, Arun Wanchoo, Karthik Chandiran, Jianbin Ruan, Sivapriya Kailasan Vanaja, Michael Bauer, Christoph Sponholz, Gregory A. Hudalla, Anthony T. Vella, Beiyan Zhou, Sachin D. Deshmukh, Gabriel A. Rabinovich, Vijay A. Rathinam
Journal: Nature Immunology (2021)
Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis
Authors: Ching‐Huang Ho, Andrea A. Silva, Jon T. Giles, Joan M. Bathon, Daniel H. Solomon, Katherine P. Liao, I‐Cheng Ho
Journal: Arthritis & Rheumatology (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Adult Mortality After Preterm Birth—Time to Translate Findings Into Clinical Practice
Authors: Casey Crump
Journal: JAMA Network Open (2021)

Kari Risnes, MD, PhD; Josephine Funck Bilsteen, MSc; Paul Brown, PhD; Anna Pulakka, PhD; Anne-Marie Nybo Andersen, MD, PhD; Signe Opdahl, MD, PhD; Eero Kajantie, MD, PhD; Sven Sandin, PhD